The Medicines Company v. Mylan, Inc. (Fed. Cir. 2017)

McDonnell Boehnen Hulbert & Berghoff LLP

The Federal Circuit returned to its consideration of the outcome in the District Court of The Medicines Company's ANDA litigation against Mylan and Bioniche Pharma over a proposed generic version of Medicines' bivalirudin drug (sold as Angiomax®), an anticoagulant used in heart surgery.  In doing so, the Court focused on claim construction, basing its decision to reverse a finding of infringement under 35 U.S.C. § 271(e)(2) on differences with the District Court's claim construction.

The invention claimed in the patents-in-suit, U.S. Patent Nos. 7,582,727 and 7,598,343, can be appreciated by the following representative claims:

Claim 1 of the '727 patent:

1.  Pharmaceutical batches of a drug product comprising bivalirudin (SEQ ID NO: 1: [Phe Pro Arg Pro Gly Gly Gly Gly Asn Gly Asp Phe Glu Glu Ile Pro Glu Glu Tyr Leu]) and a pharmaceutically acceptable carrier for use as an anticoagulant in a subject in need thereof, wherein the batches have a pH adjusted by a base, said pH is about 5-6 when reconstituted in an aqueous solution for injection, and wherein the batches have a maximum impurity level of Asp9-bivalirudin that does not exceed about 0.6% as measured by HPLC.

Claim 1 of the '343 patent:

1.  Pharmaceutical batches of a drug product comprising bivalirudin ... prepared by a compounding process comprising:
    (i) dissolving bivalirudin in a solvent to form a first solution;
    (ii) efficiently mixing a pH-adjusting solution with the first solution to form a second solution, wherein the pH-adjusting solution comprises a pH-adjusting solution solvent; and
    (iii) removing the solvent and pH-adjusting solution solvent from the second solution;
    wherein the batches have a pH adjusted by a base, said pH is about 5-6 when reconstituted in an aqueous solution for injection, and wherein the batches have a maximum impurity level of Asp9-bivalirudin that does not exceed about 0.6% as measured by HPLC.

The patents-in-suit arose from Medicines' solution to production problems with the drug, which led to the production of a degradation product, Asp9 bivalirudin (caused by deamination of Asn9); in high enough concentrations (>1.5%) Asp9 bivalirudin contaminants were unacceptable (per FDA).  Production of bivalirudin batches contaminated with high levels of Asp9 bivalirudin caused Medicines to shut down commercial production for more than a year.  The company's attempts to produce formulations of the drug for commercial sale were unsuccessful, and led Medicines to develop certain ways of adjusting the pH that reduced the impurity levels to less than 0.6% and resulted in the '343 and '727 patents.

These patents were the subject of litigation between Medicines and Hospira, where coincidentally the same panel that rendered the instant decision determined that the claims were invalid under the on-sale bar of 35 U.S.C. § 102(b)(among other grounds) (see "The Medicines Company v. Hospira (Fed. Cir. 2015)").  The Federal Circuit thereafter vacated the panel opinion and reinstituted the appeal en banc, ordering the parties (and amici) to brief issues relating to the on-sale bar and its application to the relationship between Medicines and its contract manufacturer.  The en banc court reversed the decision by the merits panel that the on-sale bar applied, in a unanimous court by Judge O'Malley (see "The Medicines Company v. Hospira, Inc. (Fed. Cir. 2016) (en banc)").

The Federal Circuit (which had dismissed Medicines' and Mylan's cross-appeals in view of the merit panel's decision in the Hospira case) then reinstated this appeal between Medicines and Mylan.  The District Court had granted summary judgment of non-infringement to Mylan as to the claims of the '343 patent, based on Mylan's ANDA specifying methods for formulating that did not use the claimed "efficient mixing" limitation of that patent's claims.  After a bench trial, the District Court had granted judgment in Medicines' favor, expressly because the '727 patent claims did not recite the "efficient mixing" limitation.

The Federal Circuit affirmed the District Court's summary judgment decision regarding the '343 patent claims, but reversed the judgment regarding the '727 patent claims, in an opinion by Judge Dyk joined by Judges Hughes and Wallach.  The Court expressly based its decision on construction of the term "batches" in the '727 patent claims, which required the use of efficient mixing methods as disclosed in the specification shared in common by both patents.  This specification defined "batches" as:

As used here, "batch" or "pharmaceutical batch" refers to material produced by a single execution of a compounding process of various embodiments of the present invention.  "Batches" or "pharmaceutical batches" as defined herein may include a single batch, wherein the single batch is representative of all commercial batches (see generally, Manual of Policies and Procedures, Center for Drug Evaluation and Research, MAPP 5225.1, Guidance on the Packaging of Test Batches at 1), and wherein the levels of, for example, Asp9-bivalirudin, total impurities, and largest unknown impurity, and the reconstitution time represent levels for all potential batches made by said process.  "Batches" may also include all batches prepared by a same compounding process.

The District Court construed the term "pharmaceutical batches" consistent with specification, to be either a single batch representative of all commercial batches "made by a compounding process" having consistent levels of all impurities (including Asp9-bivalirudin) or all batches made by the compounding process; the Federal Circuit opinion notes that the parties consented to this construction.  With regard to the term "efficient mixing," the District Court based its construction on two examples in the common specification:  one the "inefficient" mixing according to earlier Medicines' processes (Example 4), and the efficient process disclosed in the specifications (Example 5); the District Court further held that Medicines had disclaimed the old inefficient mixing process.

With regard to its review of claim construction, the opinion notes that claim construction here is reviewed as a matter of law because the District Court did not consider anything outside the intrinsic evidence, under the Supreme Court's Teva Pharmaceuticals v. Sandoz decision.  The panel based its contrary decision on the District Court's failure to interpret the "batches" limitation to require efficient mixing for the claims of the '727 patent.  The panel's rationale was that the "batches" limitation requires the claims to encompass only those having impurity levels less than 0.6%, and that this limitation cannot cover individual batches because it was undisputed that such batches were known in the prior art (i.e., batches Medicines made prior to the disruption that led to this invention).  The opinion states:  "[r]ather, properly construed, what the batches limitation requires is the use of a process that achieves batch consistency," expressly construing the "batches" claim limitation in view of the specification.  "The batches limitation therefore requires a process that achieves consistency between batches produced from the 'same compounding process'—i.e., batch consistency," said the Court.  Indeed, the panel viewed this consistency as being what distinguished these claims from the prior art (including Medicines' own prior methods and batches).  Without tying the interpretation of the term "batches" to the disclosed more efficient methods, the opinion asserts that there would be no way of effectively deciding when and whether infringement would lie.  The opinion foresees a need for "forward-looking assessments of whether future batches would infringe" (i.e., only after the batches were tested to determine the level of Asp9-bivalirudin levels).  According to the opinion:

To illustrate, if a defendant using the same compounding process produced fifty batches each having an Asp9 level below 0.6 percent, each of those fifty batches would infringe.  But the defendant would not know whether any of the batches infringed until all fifty batches had been produced because if even one of those batches was determined to have an Asp9 level higher than 0.6 percent, none of the batches would infringe.

In this regard, the opinion posits that such an interpretation would not provide the "reasonable certainty" required by Nautilus, Inc. v. Biosig Instruments, Inc., 134 S. Ct. 2120, 2129 (2014).

The opinion further found support for the Court's interpretation in the specification and prosecution history (particularly with regard to the claims patentability over inter alia the Medicines' own prior art).

Having determined that proper construction of the "batch" limitation required the use of a compounding process that achieves batch consistency, the opinion then turned to whether this compounding process must entail "efficient mixing."  Evidence for this requirement the Court found in the specification, particularly disclosure that "pH-adjusting solution will be efficiently mixed," and that "[e]fficient mixing of the pH-adjusting solution . . . will minimize levels of Asp9-bivalirudin."  Moreover, the Court states that the specification disclosed no other method capable of producing such batches with the necessary consistency (relating to the comparison between the methods disclosed in Examples 4 and 5).  The opinion also asserted that the District Court's determination that Medicines disclaimed inefficient mixing was not inconsistent with its determination that what the claims required was efficient mixing.

The opinion also rejected Medicines' contention that this interpretation would make the claims of the '343 patent "superfluous" (more accurately, implicate double patenting) by noting there may be overlap between certain of the claims but that the more specific recitations in the '343 claims distinguished them from the '727 claims.  The opinion also asserted that adopting Medicines' construction would potentially encompass the prior art, and thus impermissibly extending Medicines' "monopoly" beyond the invention disclosed in the common specification.

The Court then turned to what is meant by "efficient mixing."  This term is explicitly defined in the common specification to mean "'mixing [that] is characterized by minimizing levels of Asp9-bivalirudin in the compounding solution,' i.e., below 0.6 percent Asp9-bivalirudin in the intermediate solution."  The panel rejected this interpretation, insofar as "it does not accord with the linguistic formula used by the patentee to signal the designation of other defined terms—including 'batches.'"  By this it appears the Court meant to distinguish between how this statement was phrased and how other terms were expressly defined, i.e., where "the defined term [is] in quotation marks, followed by the terms 'refers to' or 'as defined herein.'"  The Court also rejected Medicines' assertion that its phrase was definitional on the basis that is was "a mere recitation of the results obtained" rather than constituting a definition of what "efficient mixing" is, according to the opinion.  Using Medicines' definition "would expand the scope of 'efficient mixing' to cover any way of mixing that achieves a compounding solution having an Asp9 level of less than 0.6 percent" in violation of the written description requirement, said the panel, citing Ariad Pharms., Inc. v. Eli Lilly & Co., 598 F.3d 1336, 1352–53 (Fed. Cir. 2010) (en banc).  The Court found no art-recognized definition of the term "efficient mixing," and the other portions of the specification Medicines' argued disclosed alternative methods were "vague and unhelpful" (and were not relied upon by the District Court or the parties).  Finally, the opinion (relying with some irony on Medicines' criticism of the District Court for defining "efficient mixing" with regard to what it is not, i.e., prior art methods) notes that the skilled artisan would rely upon the methods recited in Example 5 to understand what efficient mixing is.  In the Court's opinion, this Example is the only description of efficient mixing in the specification and not just an embodiment.  According to the panel, this Example provides "a clear 'objective standard by which to measure the scope of the term.'"

The opinion concluded that, in order to infringe a batch must be compounded using a efficient mixing process according to Example 5 for claims of either the '727 and '343 patents.

There is some logic underlying this decision, but it can be understood if Medicines' views the Federal Circuit's logic as imposing a definition from the specification onto the claims, contrary to the claim construction rubric that limitations should not be incorporated from the specification into the claims.  This aspect of the decision brings to mind District Court Judge Vaughn Walker's discussion of how vexatious this rule can be, as set forth his dissent in Medegen MMS, Inc. v. ICU Medical, Inc. (Fed. Cir. 2008):

The issues before the Court presented "a conundrum often faced by district courts when construing" claim terms, citing the "twin axioms" of claim construction that produced the conundrum:  "[o]n the one hand, claims 'must be read in view of the specification'," citing Markman, while "[o]n the other hand, it is improper to read a limitation from the specification into the claims," citing Arlington Indus. Inc. v.  Bridgeport Fittings, Inc.  The problem with these axioms, according to Judge Walker, is that "the axioms themselves seldom provide an answer, but instead merely frame the question to be resolved."

"As a jurist more accustomed to working on the front lines of patent litigation than reviewing decisions from above, it is my experience that claim construction -- determining how one of ordinary skill in the art would understand the patent at the time of invention -- often requires making fact-like determinations not well suited to appellate review."

The Supreme Court's decision in Teva v. Sandoz reversed the Federal Circuit's practice of giving no deference to factual underpinnings of claim construction as set forth in Cybor Corp. v. FAS Technologies, Inc.  The instant decision shows that while the problems attendant upon failure to give factual deference have been diminished they have not been overcome entirely.

The Medicines Company v. Mylan, Inc. (Fed. Cir. 2017)
Panel:  Circuit Judges Dyk, Wallach, and Hughes
Opinion by Circuit Judge Dyk

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© McDonnell Boehnen Hulbert & Berghoff LLP | Attorney Advertising

Written by:

McDonnell Boehnen Hulbert & Berghoff LLP

McDonnell Boehnen Hulbert & Berghoff LLP on:

Readers' Choice 2017
Reporters on Deadline

Related Case Law

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
- hide

JD Supra Privacy Policy

Updated: May 25, 2018:

JD Supra is a legal publishing service that connects experts and their content with broader audiences of professionals, journalists and associations.

This Privacy Policy describes how JD Supra, LLC ("JD Supra" or "we," "us," or "our") collects, uses and shares personal data collected from visitors to our website (located at (our "Website") who view only publicly-available content as well as subscribers to our services (such as our email digests or author tools)(our "Services"). By using our Website and registering for one of our Services, you are agreeing to the terms of this Privacy Policy.

Please note that if you subscribe to one of our Services, you can make choices about how we collect, use and share your information through our Privacy Center under the "My Account" dashboard (available if you are logged into your JD Supra account).

Collection of Information

Registration Information. When you register with JD Supra for our Website and Services, either as an author or as a subscriber, you will be asked to provide identifying information to create your JD Supra account ("Registration Data"), such as your:

  • Email
  • First Name
  • Last Name
  • Company Name
  • Company Industry
  • Title
  • Country

Other Information: We also collect other information you may voluntarily provide. This may include content you provide for publication. We may also receive your communications with others through our Website and Services (such as contacting an author through our Website) or communications directly with us (such as through email, feedback or other forms or social media). If you are a subscribed user, we will also collect your user preferences, such as the types of articles you would like to read.

Information from third parties (such as, from your employer or LinkedIn): We may also receive information about you from third party sources. For example, your employer may provide your information to us, such as in connection with an article submitted by your employer for publication. If you choose to use LinkedIn to subscribe to our Website and Services, we also collect information related to your LinkedIn account and profile.

Your interactions with our Website and Services: As is true of most websites, we gather certain information automatically. This information includes IP addresses, browser type, Internet service provider (ISP), referring/exit pages, operating system, date/time stamp and clickstream data. We use this information to analyze trends, to administer the Website and our Services, to improve the content and performance of our Website and Services, and to track users' movements around the site. We may also link this automatically-collected data to personal information, for example, to inform authors about who has read their articles. Some of this data is collected through information sent by your web browser. We also use cookies and other tracking technologies to collect this information. To learn more about cookies and other tracking technologies that JD Supra may use on our Website and Services please see our "Cookies Guide" page.

How do we use this information?

We use the information and data we collect principally in order to provide our Website and Services. More specifically, we may use your personal information to:

  • Operate our Website and Services and publish content;
  • Distribute content to you in accordance with your preferences as well as to provide other notifications to you (for example, updates about our policies and terms);
  • Measure readership and usage of the Website and Services;
  • Communicate with you regarding your questions and requests;
  • Authenticate users and to provide for the safety and security of our Website and Services;
  • Conduct research and similar activities to improve our Website and Services; and
  • Comply with our legal and regulatory responsibilities and to enforce our rights.

How is your information shared?

  • Content and other public information (such as an author profile) is shared on our Website and Services, including via email digests and social media feeds, and is accessible to the general public.
  • If you choose to use our Website and Services to communicate directly with a company or individual, such communication may be shared accordingly.
  • Readership information is provided to publishing law firms and authors of content to give them insight into their readership and to help them to improve their content.
  • Our Website may offer you the opportunity to share information through our Website, such as through Facebook's "Like" or Twitter's "Tweet" button. We offer this functionality to help generate interest in our Website and content and to permit you to recommend content to your contacts. You should be aware that sharing through such functionality may result in information being collected by the applicable social media network and possibly being made publicly available (for example, through a search engine). Any such information collection would be subject to such third party social media network's privacy policy.
  • Your information may also be shared to parties who support our business, such as professional advisors as well as web-hosting providers, analytics providers and other information technology providers.
  • Any court, governmental authority, law enforcement agency or other third party where we believe disclosure is necessary to comply with a legal or regulatory obligation, or otherwise to protect our rights, the rights of any third party or individuals' personal safety, or to detect, prevent, or otherwise address fraud, security or safety issues.
  • To our affiliated entities and in connection with the sale, assignment or other transfer of our company or our business.

How We Protect Your Information

JD Supra takes reasonable and appropriate precautions to insure that user information is protected from loss, misuse and unauthorized access, disclosure, alteration and destruction. We restrict access to user information to those individuals who reasonably need access to perform their job functions, such as our third party email service, customer service personnel and technical staff. You should keep in mind that no Internet transmission is ever 100% secure or error-free. Where you use log-in credentials (usernames, passwords) on our Website, please remember that it is your responsibility to safeguard them. If you believe that your log-in credentials have been compromised, please contact us at

Children's Information

Our Website and Services are not directed at children under the age of 16 and we do not knowingly collect personal information from children under the age of 16 through our Website and/or Services. If you have reason to believe that a child under the age of 16 has provided personal information to us, please contact us, and we will endeavor to delete that information from our databases.

Links to Other Websites

Our Website and Services may contain links to other websites. The operators of such other websites may collect information about you, including through cookies or other technologies. If you are using our Website or Services and click a link to another site, you will leave our Website and this Policy will not apply to your use of and activity on those other sites. We encourage you to read the legal notices posted on those sites, including their privacy policies. We are not responsible for the data collection and use practices of such other sites. This Policy applies solely to the information collected in connection with your use of our Website and Services and does not apply to any practices conducted offline or in connection with any other websites.

Information for EU and Swiss Residents

JD Supra's principal place of business is in the United States. By subscribing to our website, you expressly consent to your information being processed in the United States.

  • Our Legal Basis for Processing: Generally, we rely on our legitimate interests in order to process your personal information. For example, we rely on this legal ground if we use your personal information to manage your Registration Data and administer our relationship with you; to deliver our Website and Services; understand and improve our Website and Services; report reader analytics to our authors; to personalize your experience on our Website and Services; and where necessary to protect or defend our or another's rights or property, or to detect, prevent, or otherwise address fraud, security, safety or privacy issues. Please see Article 6(1)(f) of the E.U. General Data Protection Regulation ("GDPR") In addition, there may be other situations where other grounds for processing may exist, such as where processing is a result of legal requirements (GDPR Article 6(1)(c)) or for reasons of public interest (GDPR Article 6(1)(e)). Please see the "Your Rights" section of this Privacy Policy immediately below for more information about how you may request that we limit or refrain from processing your personal information.
  • Your Rights
    • Right of Access/Portability: You can ask to review details about the information we hold about you and how that information has been used and disclosed. Note that we may request to verify your identification before fulfilling your request. You can also request that your personal information is provided to you in a commonly used electronic format so that you can share it with other organizations.
    • Right to Correct Information: You may ask that we make corrections to any information we hold, if you believe such correction to be necessary.
    • Right to Restrict Our Processing or Erasure of Information: You also have the right in certain circumstances to ask us to restrict processing of your personal information or to erase your personal information. Where you have consented to our use of your personal information, you can withdraw your consent at any time.

You can make a request to exercise any of these rights by emailing us at or by writing to us at:

Privacy Officer
JD Supra, LLC
10 Liberty Ship Way, Suite 300
Sausalito, California 94965

You can also manage your profile and subscriptions through our Privacy Center under the "My Account" dashboard.

We will make all practical efforts to respect your wishes. There may be times, however, where we are not able to fulfill your request, for example, if applicable law prohibits our compliance. Please note that JD Supra does not use "automatic decision making" or "profiling" as those terms are defined in the GDPR.

  • Timeframe for retaining your personal information: We will retain your personal information in a form that identifies you only for as long as it serves the purpose(s) for which it was initially collected as stated in this Privacy Policy, or subsequently authorized. We may continue processing your personal information for longer periods, but only for the time and to the extent such processing reasonably serves the purposes of archiving in the public interest, journalism, literature and art, scientific or historical research and statistical analysis, and subject to the protection of this Privacy Policy. For example, if you are an author, your personal information may continue to be published in connection with your article indefinitely. When we have no ongoing legitimate business need to process your personal information, we will either delete or anonymize it, or, if this is not possible (for example, because your personal information has been stored in backup archives), then we will securely store your personal information and isolate it from any further processing until deletion is possible.
  • Onward Transfer to Third Parties: As noted in the "How We Share Your Data" Section above, JD Supra may share your information with third parties. When JD Supra discloses your personal information to third parties, we have ensured that such third parties have either certified under the EU-U.S. or Swiss Privacy Shield Framework and will process all personal data received from EU member states/Switzerland in reliance on the applicable Privacy Shield Framework or that they have been subjected to strict contractual provisions in their contract with us to guarantee an adequate level of data protection for your data.

California Privacy Rights

Pursuant to Section 1798.83 of the California Civil Code, our customers who are California residents have the right to request certain information regarding our disclosure of personal information to third parties for their direct marketing purposes.

You can make a request for this information by emailing us at or by writing to us at:

Privacy Officer
JD Supra, LLC
10 Liberty Ship Way, Suite 300
Sausalito, California 94965

Some browsers have incorporated a Do Not Track (DNT) feature. These features, when turned on, send a signal that you prefer that the website you are visiting not collect and use data regarding your online searching and browsing activities. As there is not yet a common understanding on how to interpret the DNT signal, we currently do not respond to DNT signals on our site.

Access/Correct/Update/Delete Personal Information

For non-EU/Swiss residents, if you would like to know what personal information we have about you, you can send an e-mail to We will be in contact with you (by mail or otherwise) to verify your identity and provide you the information you request. We will respond within 30 days to your request for access to your personal information. In some cases, we may not be able to remove your personal information, in which case we will let you know if we are unable to do so and why. If you would like to correct or update your personal information, you can manage your profile and subscriptions through our Privacy Center under the "My Account" dashboard. If you would like to delete your account or remove your information from our Website and Services, send an e-mail to

Changes in Our Privacy Policy

We reserve the right to change this Privacy Policy at any time. Please refer to the date at the top of this page to determine when this Policy was last revised. Any changes to our Privacy Policy will become effective upon posting of the revised policy on the Website. By continuing to use our Website and Services following such changes, you will be deemed to have agreed to such changes.

Contacting JD Supra

If you have any questions about this Privacy Policy, the practices of this site, your dealings with our Website or Services, or if you would like to change any of the information you have provided to us, please contact us at:

JD Supra Cookie Guide

As with many websites, JD Supra's website (located at (our "Website") and our services (such as our email article digests)(our "Services") use a standard technology called a "cookie" and other similar technologies (such as, pixels and web beacons), which are small data files that are transferred to your computer when you use our Website and Services. These technologies automatically identify your browser whenever you interact with our Website and Services.

How We Use Cookies and Other Tracking Technologies

We use cookies and other tracking technologies to:

  1. Improve the user experience on our Website and Services;
  2. Store the authorization token that users receive when they login to the private areas of our Website. This token is specific to a user's login session and requires a valid username and password to obtain. It is required to access the user's profile information, subscriptions, and analytics;
  3. Track anonymous site usage; and
  4. Permit connectivity with social media networks to permit content sharing.

There are different types of cookies and other technologies used our Website, notably:

  • "Session cookies" - These cookies only last as long as your online session, and disappear from your computer or device when you close your browser (like Internet Explorer, Google Chrome or Safari).
  • "Persistent cookies" - These cookies stay on your computer or device after your browser has been closed and last for a time specified in the cookie. We use persistent cookies when we need to know who you are for more than one browsing session. For example, we use them to remember your preferences for the next time you visit.
  • "Web Beacons/Pixels" - Some of our web pages and emails may also contain small electronic images known as web beacons, clear GIFs or single-pixel GIFs. These images are placed on a web page or email and typically work in conjunction with cookies to collect data. We use these images to identify our users and user behavior, such as counting the number of users who have visited a web page or acted upon one of our email digests.

JD Supra Cookies. We place our own cookies on your computer to track certain information about you while you are using our Website and Services. For example, we place a session cookie on your computer each time you visit our Website. We use these cookies to allow you to log-in to your subscriber account. In addition, through these cookies we are able to collect information about how you use the Website, including what browser you may be using, your IP address, and the URL address you came from upon visiting our Website and the URL you next visit (even if those URLs are not on our Website). We also utilize email web beacons to monitor whether our emails are being delivered and read. We also use these tools to help deliver reader analytics to our authors to give them insight into their readership and help them to improve their content, so that it is most useful for our users.

Analytics/Performance Cookies. JD Supra also uses the following analytic tools to help us analyze the performance of our Website and Services as well as how visitors use our Website and Services:

  • HubSpot - For more information about HubSpot cookies, please visit
  • New Relic - For more information on New Relic cookies, please visit
  • Google Analytics - For more information on Google Analytics cookies, visit To opt-out of being tracked by Google Analytics across all websites visit This will allow you to download and install a Google Analytics cookie-free web browser.

Facebook, Twitter and other Social Network Cookies. Our content pages allow you to share content appearing on our Website and Services to your social media accounts through the "Like," "Tweet," or similar buttons displayed on such pages. To accomplish this Service, we embed code that such third party social networks provide and that we do not control. These buttons know that you are logged in to your social network account and therefore such social networks could also know that you are viewing the JD Supra Website.

Controlling and Deleting Cookies

If you would like to change how a browser uses cookies, including blocking or deleting cookies from the JD Supra Website and Services you can do so by changing the settings in your web browser. To control cookies, most browsers allow you to either accept or reject all cookies, only accept certain types of cookies, or prompt you every time a site wishes to save a cookie. It's also easy to delete cookies that are already saved on your device by a browser.

The processes for controlling and deleting cookies vary depending on which browser you use. To find out how to do so with a particular browser, you can use your browser's "Help" function or alternatively, you can visit which explains, step-by-step, how to control and delete cookies in most browsers.

Updates to This Policy

We may update this cookie policy and our Privacy Policy from time-to-time, particularly as technology changes. You can always check this page for the latest version. We may also notify you of changes to our privacy policy by email.

Contacting JD Supra

If you have any questions about how we use cookies and other tracking technologies, please contact us at:

- hide

This website uses cookies to improve user experience, track anonymous site usage, store authorization tokens and permit sharing on social media networks. By continuing to browse this website you accept the use of cookies. Click here to read more about how we use cookies.